Sale of Future Revenue - Narrative (Details) - USD ($) $ in Thousands		2 Months Ended	3 Months Ended			9 Months Ended		29 Months Ended	47 Months Ended
	Nov. 03, 2020	Dec. 31, 2020	Sep. 30, 2024	Sep. 30, 2023	Jun. 30, 2020	Sep. 30, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024
Disaggregation of Revenue [Line Items]
Payments for loan acquisition costs						$ 18	$ 12,548
Revenues			$ 13,542	$ 13,002		45,694	37,377
Royalty
Disaggregation of Revenue [Line Items]
Revenues						(935)	$ (989)
MAM Pangolin Royalty , LLC | Maximum
Disaggregation of Revenue [Line Items]
Proceeds from sale of future revenue	$ 125,000
License agreement with Sunovion Pharmaceuticals, Inc.
Disaggregation of Revenue [Line Items]
Minimum annual royalty receivable			$ 1,000		$ 1,000	$ 1,000			$ 1,000
License agreement with Sunovion Pharmaceuticals, Inc. | Royalty
Disaggregation of Revenue [Line Items]
Revenues					$ 8,000
Monetization Agreement
Disaggregation of Revenue [Line Items]
Payments for loan acquisition costs	$ 2,909
Effective annual interest rate	24.90%
Monetization Agreement | MAM Pangolin Royalty , LLC
Disaggregation of Revenue [Line Items]
Proceeds from sale of future revenue	$ 40,000	$ 10,000						$ 50,000	$ 50,000
Proceeds from debt, contingent on additional milestones	$ 75,000